[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"keloid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:keloid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,94,115,136,156,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100645058","phase-1-a-clinical-study-on-the-safety-and-efficacy-of-wide-band-ultrasound-combined-with-traditional-chinese-medicine-preparations-in-the-prevention-and-treatment-of-keloids-100645058",false,"NCT07679243","A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids","WBUS +TCM","Inclusion Criteria:\n\nI-1 Multiple keloid lesions (≥2) on the body, requiring surgical excision and revision. The two targeted lesions shall be separated by at least 1 cm and located in the same anatomical region (e.g., abdomen, chest, upper extremity, lower leg, etc.).\n\nI-2 Aged 14 to 60 years. I-3 The targeted keloid lesions have shown no significant spontaneous regression or continuous enlargement within the past 3-6 months,or are accompanied by obvious symptoms such as itching or pain.\n\nI-4 Has fully understood the purpose, protocol, potential benefits, risks, countermeasures, and rights and obligations of the study (including privacy protection and voluntary withdrawal), and is willing to participate and cooperate well.\n\nI-5 Able to understand and sign the informed consent form, and willing to comply with treatment and follow-up.\n\nI-6 No history of allergy to any known components of the selected traditional Chinese medicine (TCM) preparation.\n\nI-7 No prior treatment for the targeted keloid lesions within 6 months before study initiation.\n\nExclusion Criteria:\n\nE-1 Currently participating in other clinical trials.E-2 Active infection or ulceration present in the targeted keloid area.E-3 Refusal to undergo surgery or biopsy for pathological confirmation.E-4 Hypertension, hypotension, or heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis, etc.).E-5 Hepatic or renal insufficiency.E-6 Infectious diseases (including viral hepatitis, syphilis, AIDS, etc.).E-7 Hematological disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).E-8 Allergic constitution (urticaria, bronchial asthma, history of allergy to more than two drugs or foods).E-9 Respiratory diseases (chronic bronchitis, emphysema, bronchiectasis, pulmonary insufficiency, chronic obstructive pulmonary disease, interstitial pneumonia).E-10 Digestive system diseases (severe gastric and duodenal ulcers, chronic gastroenteritis, chronic pancreatitis).E-11 Urinary system diseases (chronic urinary tract infection, nephritis, nephrotic syndrome).E-12 Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, etc.).E-13 Organic neurological diseases or mental illnesses (encephalitis, sequelae of brain trauma, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).E-14 Chronic skin diseases (especially infectious, allergic and inflammatory systemic skin diseases, such as generalized eczema, psoriasis, pemphigus, etc.).E-15 Autoimmune diseases and collagen diseases (such as SLE, dermatomyositis, scleroderma, etc.).E-16 History of long-term smoking, alcohol abuse, or drug abuse.E-17 History of malignant tumor within the past 5 years, currently requiring other treatments such as radiotherapy and chemotherapy.E-18 Received blood transfusion or organ transplantation from others within the past 5 years.E-19 Pregnant, lactating, menstruating, or within 1 year after termination of pregnancy.E-20 Other conditions deemed unsuitable for participation in the study by the investigator.","ALL","14 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The prevention and treatment of patients with multiple keloids throughout the body are extremely challenging. Keloids are highly resistant, refractory, and prone to recurrence, and are thus known as the \"cancer that does not kill\". At present, the main clinical strategy for such patients is staged surgical resection, followed by adjuvant local radiotherapy. When signs of recurrence appear, local injection of triamcinolone acetonide plus 5-fluorouracil (5-Fu) is administered as supplementary treatment. However, these two combination therapies have obvious limitations.\n\nAdjuvant postoperative radiotherapy is associated with a high incidence of local skin adverse reactions, including radiodermatitis and delayed wound healing. Late complications may occur weeks or months after treatment, such as permanent hyperpigmentation and hypopigmentation, skin atrophy, fibrosis, scabbing and desquamation, and intractable ulcers. In addition, radiotherapy is not suitable for some young female patients and children when keloids are located near organs such as the thyroid gland and gonads.\n\nInjection of triamcinolone acetonide plus 5-Fu causes significant pain and requires repeated sessions. Potential risks include local ulceration, hyperpigmentation, telangiectasia, and menstrual irregularities in female patients. Therefore, there is an urgent clinical need for a pathological scar prevention and treatment technique that can rapidly relieve discomfort, promote scar atrophy, cause no secondary injury, carry low risks, have a short recovery period, provide high comfort during treatment, and be applicable to large-area or multiple pathological scars across the body.\n\nOur research team previously observed in clinical practice that wide-band ultrasound (Universal Beauty® Type I Ultrasound Therapeutic Device) combined with traditional Chinese medicine (TCM) preparations can release abnormally accumulated and contracted collagen fibers in scar tissue via ultrasonic energy. Meanwhile, ultrasound promotes the penetration of TCM into scar lesions, exerting effects of infection control, inflammation inhibition, subsidence of redness and swelling, and relief of itching and pain.\n\nCompared with conventional scar therapies, this approach achieves rapid symptom control, no secondary damage, no obvious side effects, a short recovery period, and high treatment comfort. It shows particularly significant advantages for large-area or multiple pathological scars throughout the body that are difficult to treat with traditional methods. Preliminary treatment in a small number of volunteers with multiple keloids has achieved satisfactory outcomes without obvious adverse reactions.\n\nThe purpose of this study is to verify the efficacy and safety of wide-band ultrasound combined with TCM preparation (Chuang Li Fu) in the prevention and treatment of keloids through this clinical trial.",[28],"Keloid",[30,31,32],"keloid","Wide-Band Ultrasound","Traditional Chinese Medicine","NOT_YET_RECRUITING","2026-06-25",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":21},"2026-08-01",{"date":41,"type":21},"2028-10-31",{"name":43,"class":44},"Fujian Medical University Union Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100641285","phase-1-analyse-of-diagnosis-value-of-keloid-on-68ga-rgd-pet-ct-100641285","NCT07660406","Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT","Inclusion Criteria:\n\n\\- Patients with a clinical diagnosis of keloids Able to obtain informed consent\n\nExclusion Criteria:\n\n\\- Pregnant women, children, patients with allergies to contrast media Patients with claustrophobia","18 Years","80 Years",{"count":54,"type":21},30,[24,25],"Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET\u002FCT may provide evidence for diagnosis and evaluate the effectiveness of treatment.",[28],"RECRUITING","2026-06-17",{"date":61,"type":37},"2026-06-22",{"date":63,"type":37},"2024-08-01",{"date":65,"type":21},"2027-10",{"name":67,"class":44},"Peking Union Medical College Hospital",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":68},"100180154","genetic-analysis-of-keloids-100180154","NCT01619553","Genetic Analysis of Keloids","Identification of Genetic Variants That Contribute to Keloid Formation in Families and Isolated Cases.","Inclusion Criteria:\n\n* keloids;\n* unaffected individuals only if part of a participating keloid family\n\nExclusion Criteria:\n\n* no keloids;\n* unaffected individuals only as part of a participating keloid family",{"count":77,"type":21},7000,"OBSERVATIONAL","Keloids have a strong genetic component. The goal of this study is to identify genes and regulatory elements on chromosomes that are the cause for keloids or contribute to keloid scarring.",[28],[30,82,83,84],"fibrosis","wound healing","scar","2026-04-14",{"date":87,"type":37},"2026-04-15",{"date":89,"type":4},"2009-04",{"date":91,"type":21},"2030-12",{"name":93,"class":44},"UConn Health",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100633398","intralesional-cryosurgery-alone-versus-combined-with-5-fu-and-triamcinolone-for-keloids-100633398","NCT07526168","Intralesional Cryosurgery Alone Versus Combined With 5-FU and Triamcinolone for Keloids","Efficacy and Safety of Intralesional Cryosurgery Alone and in Combination With Intralesional 5-fluorouracil\u002FTriamcinolone Acetonide Injection for Treatment of Keloids: a Comparative Clinical Study","Inclusion Criteria:\n\n* Adult patients (≥18 years) with clinically diagnosed keloids .\n* Keloids of size 1-10 cm in greatest dimension .\n* Keloids of at least one year duration\n\nExclusion Criteria:\n\n* Females who are pregnant, planning pregnancy, or lactating .\n* Hypertrophic scars .\n* Chronic kidney or liver disease (relevant for 5-FU safety) .\n* Patients with active inflammation, infection, or ulcer at or around the keloid or Lesions suspicious for malignancy .\n* Patients who received any treatment for the same keloid in the past 12 months .\n* Immunosuppressed patients or those with chronic inflammatory diseases .",{"count":102,"type":21},32,[104],"NA","evaluate the efficacy and safety of intralesional cryosurgery alone compared with intralesional cryosurgery combined with intralesional 5-fluorouracil and triamcinolone acetonide in the treatment of keloids.",[28],"2026-04-10",{"date":109,"type":37},"2026-04-13",{"date":36,"type":21},{"date":112,"type":21},"2027-08-01",{"name":114,"class":44},"Assiut University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":68},"100417942","radiotherapy-for-keloids-100417942","NCT04722263","Radiotherapy for Keloids","Primary Radiotherapy for the Treatment of Keloids: A Pilot Study","Inclusion Criteria:\n\n* Clinically diagnosed keloid\n* Surgical excision of keloid is either contraindicated or patient has declined treatment with surgical excision (Note: patients with keloids that recurred after previous resection are eligible, as long as the current keloid is either unresectable or patient has declined resection)\n* Age ≥ 18\n* Study specific informed consent provided\n\nExclusion Criteria:\n\n* Prior RT to the area of interest that would result in overlap of radiation therapy fields\n* Females of child bearing age without a negative serum pregnancy test prior to initiation of RT or unwilling to use contraception prior to and during the radiation course\n* Keloids in areas where radiation therapy introduces unacceptable high risk of toxicity as determined by the treating radiation oncologist\n* Uncontrolled intercurrent illness (e.g. symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or psychiatric situation) that would limit compliance with study requirements as judged by the treatment physicians",{"count":123,"type":21},15,[104],"The purpose of this pilot study is to evaluate the safety and efficacy of radiation therapy (RT) in the treatment of unresected keloids.",[28],"2026-01-27",{"date":129,"type":37},"2026-01-30",{"date":131,"type":37},"2020-12-01",{"date":133,"type":21},"2026-06",{"name":135,"class":44},"Montefiore Medical Center",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":68},"100544789","phase-2-ritlecitinib-in-patients-with-keloids-or-those-undergoing-keloidectomy-100544789","NCT06373458","Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy","A Single-Center, Two-Arm, Open-Label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib in Patients With Keloid","Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age at the time of signing the informed consent document (not more than 10% of the patients can be \\> 50 years of age).\n* Patient is able to understand and voluntarily sign an informed consent document prior to participation in any study assessments or procedures.\n* Patient is able to adhere to the study visit schedule and other protocol requirements.\n* Patients who receive keloidectomy at Day 1\u002F Baseline only (Group 1): Patient has minimum of one keloid measuring ≥2 cm in length on earlobe or ≥3.0 cm in length on areas) other than earlobe, which has failed prior minimally invasive treatments for keloids including topicals and intralesional corticosteroid injections and that can be surgically resected at Day 1\u002F Baseline.\n* Patients who do not receive keloidectomy at Day 1\u002F Baseline only (Group 2):\n\n  * Patient has a minimum of either one keloid measuring ≥3 cm in length, or multiple keloids, each measuring ≥1 cm in length , which failed prior minimally invasive treatments for keloids including topicals and intralesional corticosteroid injections. However, at least one keloid should not have been treated with surgery, cryotherapy, radiation, or any other procedure that leads to a deformity that interferes with proper clinical assessments.\n  * Patient reports either Pain-NRS ≥4 , Itch-NRS ≥4, or DLQI ≥8both at Visit 1 (Screening) and Visit 2 (Baseline)\n* Patient is judged to be in otherwise good overall health as judged by the investigator, based on medical history, physical examination, and laboratory testing. (NOTE: The definition of good health means a patient does not have uncontrolled significant co-morbid conditions).\n* Ability to take oral medication without crushing, dissolving or chewing tablets.\n* Females of childbearing potential (FOCBP) must have a negative pregnancy test at Screening and Day 1\u002F Baseline. While on ritlecitinib and for at least 28 days after taking the last dose of ritlecitinib, FOCBP who engage in activity in which conception is possible must use the approved contraceptive methods.\n\nExclusion Criteria:\n\n* Patient has a persistent or recurring bacterial infection requiring systemic antibiotics, or clinically significant viral or fungal or helminth parasitic infections, within 2 weeks of the Screening Visit. Any treatment of such infections must have been completed at least 2 weeks prior to the Screening Visit and no new\u002Frecurrent infections should have occurred prior to the Baseline Visit.\n* Patient with current or history of positive human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency (i.e., Common Variable Immunodeficiency \\[CVID\\]), or active or untreated latent tuberculosis.\n* Infected with hepatitis B or C virus.\n* Patients who have history of single episode of disseminated herpes zoster (HZ) or disseminated herpes simplex or recurrent (\\> 1 episode of) localized dermatomal HZ\n* Patient has clinically significant (as determined by the investigator) renal, hepatic, hematologic, intestinal, endocrine, pulmonary, cardiovascular, neurological, psychiatric, immunologic, or other major uncontrolled diseases that will affect the health of the patient during the study or interfere with the interpretation of study results.\n* Patient has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis.\n* Any gastrointestinal or metabolic condition that could interfere with the absorption of the oral medication.\n* Active alcohol and\u002For drug abuse.\n* History of thrombosis\u002F thromboembolic event, known coagulopathy.\n* Additional skin disease that might interfere with keloid clinical assessments.\n* Have hearing loss with progression over the previous 5 years, or sudden hearing loss, or middle or inner ear disease including otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered acute, fluctuating, or progressive.\n* Patient has received a live attenuated vaccine ≤ 30 days prior to study initiation.\n* History of adverse systemic or allergic reactions to any component of the study drug.\n* Recent surgery excluding keloidectomy within 4 weeks and keloidectomy within 6 months prior to trial initiation.\n* Recent cryotherapy within 3 months, laser therapy within 3 months, or radiation or any other procedure within 6 months.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, or ultraviolet (UV) phototherapy with or without Psoralen Ultraviolet A (PUVA) therapy within 4 weeks prior to trial initiation. Compression garments and silicone sheets may be allowed.\n* Treatment with medication that might interfere with blood levels or have a major impact on the clinical readout of the study drug. This includes the following:\n\n  * Patient on concomitant medications that are substrates of CYP3A4 or CYP1A2 with narrow therapeutic index where small concentration changes may lead to serious adverse reactions\n  * Patient on concomitant medications that are strong inducers of CYP3A4 as this might cause loss of efficacy of ritlecitinib\n* Use of an oral JAK inhibitor (tofacitinib, ruxolitinib, ritlecitinib) within 3 months prior to the Baseline visit.\n* Patient has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus, and\u002For topical chemotherapy on any keloid lesions within 2 weeks prior to the Baseline visit. These will be allowed during the study on areas other than keloid lesions (if applicable) but not on any keloid lesions.\n* Female patient who is pregnant or breast feeding\n* FOCBP with unwillingness or inability to use a contraception method during the time of participation in the trial (Appendix 1)\n* Abnormality in hematology, chemistry profiles, and ECG during screening:\n\n  * Platelet count: \\\u003C75000\u002F mm3\n  * Lymphocytes: \\\u003C600\u002F mm3\n  * Absolute neutrophil count: \\\u003C1200\u002F mm3\n  * Hemoglobin: \\\u003C9.0 g\u002FdL\n  * ALT or AST: \\>3.0xULN\n  * eGFR: \\\u003C30 mL\u002Fmin\n  * ECG that demonstrates clinically relevant abnormalities that may affect patient safety",{"count":54,"type":21},[25],"Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3\u002FTEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis.",[28],"2025-09-29",{"date":149,"type":37},"2025-09-30",{"date":151,"type":37},"2024-08-13",{"date":153,"type":21},"2027-08",{"name":155,"class":44},"Icahn School of Medicine at Mount Sinai",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":163,"sex":16,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":68},"100526762","phase-2-comparing-the-effect-of-sisparc-microneedle-patch-versus-sisparcsilr4a-microneedle-patch-on-post-surgical-scars-100526762","NCT06138964","Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars","Randomized Intra-individually Controlled Double-blinded Trial Comparing Effect of Small Interfering RNA Against SPARC (siSPARC) Microneedle Patch Versus Small Interfering RNA Against SPARC and IL4-RA (siSPARC + siLR4A) Microneedle Patch on Appearance of Post-surgical Scars","Inclusion Criteria:\n\n* Adult\n* Age 21-75\n* 2 weeks (+\u002F- 7 days) after surgical operation with incision into the dermis\n* Post-stitch removal when stitches were applied\n* Wound closure\u002Funion achieved\n\nExclusion Criteria:\n\n* Pregnant or lactating participant\n* Participants with wound infection\n* Participants assessed to be uncooperative or unable to self-administer the interventions\n* Participants with known contact allergy to ingredients in the patch formulation (comprising hyaluronic acid, siRNA and glue) and\u002For isopropyl alcohol\n* Participants who are unable to personally consent (for e.g., cognitively impaired)",true,"21 Years","75 Years",{"count":167,"type":21},50,[25],"This randomized, double-blind controlled study aims to compare the effect on appearance of post- surgical scars between daily application of siSPARC microneedle patch versus siSPARC + siLR4A microneedle patches. These are patches comprising short microneedles embedded with hydrolysed RNA (siRNAs).",[28,171,172],"Wound Heal","Wound","2024-06-20",{"date":175,"type":37},"2024-06-24",{"date":177,"type":37},"2023-11-14",{"date":179,"type":21},"2024-11-14",{"name":181,"class":182},"National Skin Centre","NETWORK",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":68},"100165229","web-based-investigation-of-natural-history-of-keloid-disorder-an-online-survey-100165229","NCT01423981","Web Based Investigation of Natural History of Keloid Disorder, an Online Survey","Inclusion Criteria:\n\n1. Patients must have clinically confirmed diagnosis of keloid\n2. Adults, age over 18\n3. Parent or legal guardian may participate if patient is under the age of 18\n4. Able and willing to complete a web based survey\n\nExclusion Criteria:\n\n* No one will be excluded from this study as long as the inclusion criteria are met.",{"count":190,"type":21},10000,"This trial intends to gather very basic clinical information about keloid, its patterns of presentation, family history, ethnic background and correlation with the type of keloid, as well as prior treatment results that patients have had received.",[28],[28,194,195,196],"Scar","hypertrophic scar","familial keloid","2016-10-03",{"date":199,"type":21},"2016-10-04",{"date":201,"type":4},"2011-11",{"date":203,"type":21},"2031-06",{"name":205,"class":206},"Tirgan, Michael H., M.D.","INDIV"]